reviewTop 10% cited
Developing new metal-based therapeutics: challenges and opportunities
Dalton Transactions · 2007 · pp. 4929–4929
Trevor W. Hambley✉(University of Sydney)
Abstract
Unexpected side effects and problems experienced in clinical trials have created a difficult environment for those developing new pharmaceuticals and, as a consequence, the number of new chemical entities being registered has fallen to a historic low. Those developing metal-based therapeutics will face the same difficulties, but this environment also provides many opportunities for creative solutions to be applied to overcoming the problems and concerns. In this perspective, these challenges and opportunities are considered in the context of examples of a number of classes of metal-based therapeutics.
Nanomaterials for catalytic reactionsPharmacological Effects and Toxicity StudiesAsymmetric Hydrogenation and CatalysisPerspective (graphical)Context (archaeology)Face (sociological concept)Risk analysis (engineering)Engineering ethicsComputer scienceNanotechnologyData scienceMedicineEngineering
MeSH terms
MetalsModels, MolecularRadioisotopesDrug Design
Citations
332
FWCI
7.51
field-weighted impact
References
81
Percentile
98%
vs. same field & year
Citations per year
References
Metal-based antitumour drugs in the post genomic era
Dalton Transactions · 2006 · 760 citations
Drug penetration in solid tumours
Nature reviews. Cancer · 2006 · 2,726 citations
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
Clinical Cancer Research · 2005 · 1,023 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
